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IMPORTANCE Patients with congenital heart disease (CHD), the most common birth defect,
have increased risks for cancer. Identification of the variables that contribute to cancer risk is
essential for recognizing patients with CHD who warrant longitudinal surveillance and early
interventions.
OBJECTIVE To compare the frequency of damaging variants in cancer risk genes among
patients with CHD and control participants and identify associated clinical variables in
patients with CHD who have cancer risk variants.
DESIGN, SETTING, AND PARTICIPANTS This multicenter case-control study included
participants with CHD who had previously been recruited to the Pediatric Cardiac Genomics
Consortium based on presence of structural cardiac anomaly without genetic diagnosis at the
time of enrollment. Permission to use published sequencing data from unaffected adult
participants was obtained from 2 parent studies. Data were collected for this study from
December 2010 to April 2019.
EXPOSURES Presence of rare (allele frequency, <1 × 10−5) loss-of-function (LoF) variants in
cancer risk genes.
MAIN OUTCOMES AND MEASURES Frequency of LoF variants in cancer risk genes (defined in
the Catalogue of Somatic Mutations in Cancer–Cancer Gene Consensus database), were
statistically assessed by binomial tests in patients with CHD and control participants.
RESULTS A total of 4443 individuals with CHD (mean [range] age, 13.0 [0-84] years; 2225 of
3771 with reported sex [59.0%] male) and 9808 control participants (mean [range] age, 52.1
[1-92] years; 4967 of 9808 [50.6%] male) were included. The frequency of LoF variants in
regulatory cancer risk genes was significantly higher in patients with CHD than control
participants (143 of 4443 [3.2%] vs 166 of 9808 [1.7%]; odds ratio [OR], 1.93 [95% CI,
1.54-2.42]; P = 1.38 × 10−12), and among CHD genes previously associated with cancer risk (58
of 4443 [1.3%] vs 18 of 9808 [0.18%]; OR, 7.2 [95% CI, 4.2-12.2]; P < 2.2 × 10−16). The LoF
variants were also nominally increased in 14 constrained cancer risk genes with high
expression in the developing heart. Seven of these genes (ARHGEF12, CTNNB1, LPP, MLLT4,
PTEN, TCF12, and TFRC) harbored LoF variants in multiple patients with unexplained CHD.
The highest rates for LoF variants in cancer risk genes occurred in patients with CHD and
extracardiac anomalies (248 of 1482 individuals [16.7%]; control: 1099 of 9808 individuals
[11.2%]; OR, 1.59 [95% CI, 1.37-1.85]; P = 1.3 × 10−10) and/or neurodevelopmental delay (209
of 1393 individuals [15.0%]; control: 1099 of 9808 individuals [11.2%]; OR, 1.40 [95% CI,
1.19-1.64]; P = 9.6 × 10−6).
CONCLUSIONS AND RELEVANCE Genotypes of CHD may account for increased cancer risks. In
this cohort, damaging variants were prominent in the 216 genes that predominantly encode
regulatory proteins. Consistent with their fundamental developmental functions, patients
with CHD and damaging variants in these genes often had extracardiac manifestations. These
data may also implicate cancer risk genes that are repeatedly varied in patients with
unexplained CHD as CHD genes.
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T he growing population of adults with congenitalheart disease (CHD)1 has created increased recogni-tion of additional health issues, including a 1.4-fold to
2-fold higher cancer prevalence than in the general
population.2-4 While radiation exposure from therapeutic
interventions can increase cancer risk (CR),5 the diversity of
malignant conditions outside of radiation fields suggests
other risk factors.3 Additional risks and mechanisms that
link CHD to cancer are unknown.
Damaging gene variants contribute to both CHD6,7 and
cancer,8 hinting that these disorders share molecular rela-
tionships. This model is supported by the increased preva-
lence of damaging variants in CR genes among children with
developmental delays,9 including autism and intellectual
disabilities, which occur in some patients with CHD. To
explore potential molecular relationships, we analyzed rare
loss-of-function (LoF) variants in CR genes among a large
CHD cohort and defined accompanying clinical features.
These analyses identify patients with CHD and the highest
CR gene burden, who may warrant longitudinal cancer
screening.
Methods
Study Participants and Ethical Approval
The multicenter case-control study was reviewed and ap-
proved by the relevant institutional review boards, including
at Boston Children’s Hospital. Written informed consent was
obtained at the time of enrollment. We studied participants in
the Pediatrics Cardiovascular Genetics Consortium7 with un-
defined causes for CHD at the time of enrollment and unaf-
fected control participants in studies of autism7 and
schizophrenia10 (eTable 1 in the Supplement).
CR Genes
The Catalogue of Somatic Mutations in Cancer–Cancer Gene
Consensus database defines 723 CR genes (eTable 2 in the
Supplement).8 This includes 38 CR genes that also cause CHD
(eTable 3 in the Supplement and Online Mendelian Inheri-
tance in Man [OMIM]; https://omim.org/), 216 CR genes that
regulate RNA transcription or processing, and 227 CR genes
with LoF mechanisms, including 107 genes with LoF germ-
line mechanisms.
Variant Calls and Statistical Analyses
Whole-exome sequences from patients with CHD and con-
trol partic ipants were processed using established
pipelines7 to identify rare (allele frequency, ≤1 × 10−5) het-
erozygous LoF variants. All P values reflect binomial tests
after Bonferroni correction with a P value threshold of
1.67 × 10−3 (10 gene lists and 3 comparisons). A false discov-
ery rate P < .05 was used as the significant threshold
throughout. The eMethods in the Supplement includes fur-
ther methodological details. Data were collected for this
study from December 2010 to April 2019. The software pro-
gram R version 3.6.0 (R Foundation for Statistical Comput-
ing) was used for analysis.
Results
LoF Variants in CR Genes Among Patients With CHD
Initial analyses of LoF variants in CR genes (eTable 4 and
eMethods in the Supplement) and prespecified subsets (Table 1)
demonstrated significantly higher frequencies in patients with
CHD who were randomly assigned to the discovery group
(n = 2222) or the replication group (n = 2221) in comparisons
with independent control cohorts (n = 3578 and n = 6230;
eTables 5 and 6 in the Supplement). As such, we present com-
bined data from 4443 patients with CHD and 9808 control par-
ticipants (Table 1). Patients with CHD ranged in age from 0 to
84 years, with a mean (SD) age of 13.0 (14.8) years; 2225 of 3771
patients with CHD with a reported sex (59.0%) were male. Con-
trol participants ranged in age from 21 to 92 years, with a mean
(SD) age of 52.1 years, and 4967 of 9808 participants (50.6%)
were male.
The presence of CR variants was not associated with any
specific CHD subtype (eTable 7 in the Supplement). Most pa-
tients with CHD (599 of 642 [93.3%]) had a single CR variant,
while a minority had 2 CR vaiants (43 of 642 [6.7%]) or 3 CR
variants (3 of 642 [0.5%]). No individual had 2 independent
CR variants in the same gene. Analyses restricted to partici-
pants of European ancestry (CHD: 448 of 3106 individuals
[14.4%]; controls: 849 of 9501 individuals [8.9%]) remained
significant (odds ratio [OR], 1.72 [95% CI, 1.52-1.94];
P < 2.2 × 10−16; eTable 8 in the Supplement). Because many CR
genes are associated with adult-onset malignant conditions,
we compared LoF variant frequencies in patients with CHD who
were younger than 16 years (n = 3338) or older than 16 years
(n = 1105). A higher proportion of older individuals had LoF
variants, albeit with comparable ORs (1.33-1.37; eTable 9 in the
Supplement).
Thirty-eight CR genes have dominant patterns of trans-
mission for CHD (denoted OMIM; Table 1); these genes had sig-
nificantly more LoF variants in patients with CHD than con-
trol participants (OR, 7.19 [95% CI, 4.23-12.22]; P < 2.2 × 10−16).
The presence of LoF variants was also increased among CR
genes with regulatory functions (OR, 1.93 [95% CI, 1.54-
2.42]; P = 1.38 × 10−12), a prominent feature of many CR and
Key Points
Question Do damaging gene variants account for increased
cancer risk in patients with congenital heart disease (CHD)?
Findings In this case-control study, loss-of-function variants in
cancer risk genes were increased approximately 1.3-fold in 4443
patients with CHD compared with 9808 control participants. This
burden was highest in cancer risk genes previously associated with
CHD (7.2-fold) or that regulate gene expression (1.9-fold); patients
with CHD and extracardiac anomalies and/or neurodevelopmental
delay had the highest rates of damaging variants in cancer risk
genes.
Meaning Genetic analyses of patients with CHD may identify
precise causes of heart malformations and also patients with CHD
and increased cancer risks.
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CHD genes. Genes found in both categories (OMIM and regu-
latory; n = 17) had the highest frequency of LoF variants in in-
dividuals with CHD (OR, 9.89 [95% CI, 4.80-20.40];
P < 2.2 × 10−16). The CR genes with dominant variants that
cause cancer by haploinsufficiency (n = 46) were also en-
riched in those with CHD (OR, 2.36 [95% CI, 1.60-3.47];
P = 3.45 × 10−8; Table 1).
Comorbidities in Patients With CHD and LoF Variants
in CR Genes
Damaging CR variants are increased in individuals with de-
velopmental delays.9 Because these delays can occur with CHD,
we partitioned patients into those with extracardiac anoma-
lies (ECA; n = 1482), neurodevelopmental defects (NDD;
n = 1393), both ECA and NDD (n = 878), and neither ECA or NDD
(isolated CHD; n = 1379). The LoF variants in CR genes were
highest among patients with CHD and ECA (CHD: 248 of 1482
individuals [16.7%]; control: 1099 of 9808 individuals [11.2%];
OR, 1.59 [95% CI, 1.37-1.85]; P = 1.3 × 10−10; eTable 9 in the
Supplement) and patients with CHD and NDD (CHD: 209 of
1393 individuals [15.0%]; control: 1099 of 9808 individuals
[11.2%]; OR, 1.40 [95% CI, 1.19-1.64]; P = 9.6 × 10−6), while the
LoF in CR genes in patients with isolated CHD was compa-
rable with that of control participants. Notably, 10 genes had
LoF variants in 3 or more patients with CHD and NDD or CHD
and ECA (supporting cohort size for statistics: CHD: 1482 in-
dividuals with ECA and 1393 with NDD; control: 9808 indi-
viduals; P < .05), including 2 CR regulatory genes (catenin beta
1 [CTNNB1; in 3 participants with CHD and ECA, 2 with CHD
and NDD, and 0 control participants) and transcription factor
12 [TCF12; in 3 patients with CHD and NDD, 2 patients with CHD
and ECA, and 2 control participants]; eTable 10 in the Supple-
ment). However, we observed no significant functional en-
richment in genes with LoF variants within each CHD group
(eMethods in the Supplement).
CR Genes as Candidate CHD Genes
Given the dual role of some genes in both CHD and cancer, we
considered if some CR genes might contribute to CHD. When
considering only patients with CHD without pathogenic vari-
ants in OMIM CHD genes (n = 4293), we identified signifi-
cantly more LoF variants in affected individuals (576 in 4293
[13.4%]) than control participants (1080 of 9744 [11.1%];
P = 1.2 × 10−6; OR, 1.24 [95% CI, 1.12-1.39]; eTable 9 in the
Supplement). Moreover, 7 CR genes that are LoF intolerant
(probability of LoF intolerance by the Genome Aggregation Da-
tabase, >0.50) and highly expressed in the developing heart
had LoF variants in 3 or more patients with unexplained CHD
(rho guanine nucleotide exchange factor 12 [ARHGEF12],
CTNNB1, lipoma-preferred partner [LPP], afadin [MLLT4],
phosphatase and tensin homolog [PTEN], TCF12, and trans-
ferrin receptor [TFRC] genes; Table 2).
Discussion
In a large CHD cohort, we demonstrated an increased preva-
lence of LoF variants in CR genes, particularly those with es-
tablished roles in CHD or that regulate gene expression (Table 1).
Patients with CHD and variants in the CR genes were more likely
to have ECA and/or NDD (eTable 9 in the Supplement), thereby
prioritizing patients for prospective studies to determine if
clinical outcomes validate CR. Importantly, we identified no
increase rates of LoF in CR genes among patients with iso-
lated CHD. Additionally, our data (Table 2) indicate that LoF
variants in some CR genes contribute to CHD, prioritizing new
molecules for mechanistic studies in heart development.
Recent genetic analyses6,7,11,12 demonstrate that many
CHD genes function in regulating the epigenome and gene
transcription and translation—processes that are critical to
orchestrating cardiac progenitor cell proliferation, lineage
commitment, and differentiation. These genes broadly par-
ticipate in human development and harbor the highest rates
of damaging variants among patients with CHD and ECA or
NDD.6,11 Stem cells, with germline and somatic variants in
genes with similar key functions, cause cancer.13-15 That sub-
sets of patients with CHD (with ECA or NDD; eTable 9 in the
Supplement) had the highest burden of LoF variants in these
CR genes emphasizes the broad expression patterns and
shared molecular mechanisms for some developmental
Table 1. Patients With Congenital Heart Disease (CHD) and Rare Loss-of-Function (LoF) Variants
in Subsets of the Catalogue of Somatic Mutations in Cancer–Cancer Gene Consensus Cancer Risk Genes
Genes No.
Patients
with CHD
Control
participants
Odds ratio
(95% CI)
Binomial
P valuea
Total participants 14 251 4443 9808 NA NA
All cancer risk 723 642 1099 1.34 (1.21-1.49) 2.31 × 10−11b
OMIM CHDc 38 68 18 7.19 (4.23-12.22) <2.2 × 10−16b
Regulatory 216 143 166 1.93 (1.54-2.42) 1.38 × 10−12b
Regulatory and OMIM CHDc 17 40 9 9.89 (4.80-20.40) <2.2 × 10−16b
Regulatory without OMIM CHDc 199 103 157 1.46 (1.13-1.88) 2.01 × 10−4
Non-OMIM CHD 685 585 1082 1.22 (1.10-1.36) 5.245 × 10−6
Nonregulatory 507 516 942 1.24 (1.10-1.39) 5.46 × 10−6
LoF cancer mechanism 227 240 376 1.43 (1.21-1.69) 1.58 × 10−7
Recessive LoFd 135 158 274 1.28 (1.05-1.57) 1.68 × 10−3
Dominant LoFd 46 53 50 2.36 (1.60-3.47) 3.45 × 10−8b
Non-LoF cancer mechanism 496 422 751 1.27 (1.12-1.43) 4.46 × 10−6
Abbreviations: NA, not applicable;
OMIM, Online Mendelian Inheritance
in Man.
a Bonferroni significance P value
threshold: 1.67 × 10−3 (10 gene lists
by 3 comparisons).
b Significant in both subanalyses.
c The OMIM CHD genes with
dominant patterns of transmission.
d Five genes have both dominant and
recessive cancer variants; 51 are not
characterized.
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defects and cancer. By contrast, damaging variants in genes
with highly enriched expression in the heart, a tissue with
exceedingly rare cancers, may preferentially cause isolated
CHD and convey low CR.
Patients with CHD have common CR factors found in the
general population, while our data indicate that CHD geno-
types can contribute additional CR. Prior studies defined this
association in a few CHD genes, including the lysine methyl-
transferase 2D (MLL2/KMT2D) gene, which encodes a chro-
matin modifier with broad tissue expression. Dominant de
novo LoF variants in MLL2/KMT2D cause Kabuki syndrome
with CHD,12 while somatic variants cause lung and colon
adenocarcinomas.8 Our data extend these recognized link-
ages by defining more CR genes in more patients with CHD and
indicating potentially shared disease mechanisms. For ex-
ample, dysregulated vascular endothelial growth factor sig-
naling from damaging variants in the kinase insert domain re-
ceptor (KDR) gene, which encodes a vascular endothelial
growth factor receptor, could account for malformations of the
great vessels6,7 and cancer-associated angiogenesis.
Biallelic variants are often required for oncogenesis,8,14
whereas 1 damaging variant is often sufficient to perturb
cardiac morphogenesis. This raises the possibility that dam-
aging variants in patients with CHD set the stage but do not
directly initiate oncogenesis. Increased CR likely reflects
additional, amplifying factors, including radiation and other
CHD-associated exposures. Consistent with this model, we
note that dominant MLL2/KMT2D variants cause CHD,6,7,11
while biallelic loss occurs in many cancers. We propose that
CR is increased because the germline variant provides the
first of 2 hits needed for cancer to emerge. Across this CHD
cohort, 3.6% had LoF variants in recessive CR genes, while
1.8% had LoF variants in dominant CR genes. We speculate
that high lifetime radiation doses might increase somatic
variants that complement CHD LoF variants.
Limitations
This study has limitations, including the young ages of the pa-
tients with CHD and the need for longitudinal cancer surveil-
lance to benchmark the clinical relevance of CR variants in pa-
Table 2. Seven Cancer Risk Genes With Multiple Loss-of-Function (LoF) Variants in Patients With Unexplained Congenital Heart Disease (CHD)
Gene
CHD
LoF
Non-
CHD
LoF pLI
Heart
expression
rank
Human
CHD
gene
CR
regula-
tory
gene
Known gene
syndrome/
phenotype
No. of
patients
with CHD
and CHD
and ECA
phenotype
data
CHD
phenotypes
(No. of
patients)
No. of patients
with CHD and ECA
phenotypes
Proportion
of patients
with CHD
and NDD,
No./total No.
KDR 7 0 0.98 87 No No Hemangioma 3 LVOTO (1)
and ToF (2)
1 With microcephaly,
micrognathia, inguinal
hernia, cryptorchidism,
and hydrocephalus
1/1
TCF12 5 2 0.97 89 No Yes Craniosynostosis 5 ASD (1),
Ebstein
anomaly (1),
and LVOTO
(3)
2 With bitemporal
narrowing (1),
abdominal heterotaxy
(1), absent corpus
callosum and seizure
disorder (1), and/or
neonatal AML (1)
3/3
CTNNB1 3 0 1 99 No Yes Neurodevelop-
mental disorder
3 ASD (1),
dilated
tricuspid
valve (1), and
ToF(1)
3 With microcephaly (2),
strabismus (2),
astigmatism (1),
micrognathia (1),
congenital scoliosis (1),
and/or hypotonia (2)
2/2
ARHGEF12 3 0 1 91 No No None 3 ASD (2) and
truncus
arteriosus (1)
1 With hearing loss 3/3
MLLT10 3 0 1 85 No Yes None 2 ASD or VSD
(1) and
LVOTO (1)
None with ECA 1/1
PTEN 3 1 0.98 78 No No Cowden 3 ASD (2) and
VSD (1)
2 With macrocephaly
(2), airway malacia (1),
congenital scoliosis and
abnormal vertebrae (1),
Chiari malformation and
hydrocephalus (1),
and/or Cowden features
(1)
2/2
TFRC 3 1 0.78 82 No No Immunodeficiency 3 Pulmonary
atresia/
stenosis (2)
and ToF (1)
2 With frontal bossing
(1), and/or intestinal
atresia and VATER
association (1)
1/1
Abbreviations: AML, acute myelogenous leukemia; ARHGEF12, rho guanine
nucleotide exchange factor 12 gene; ASD, atrial septal defect; CTNNB1, catenin
beta 1 gene; ECA, extracardiac anomaly; KDR, kinase insert domain receptor
gene; LVOTO, left ventricular outflow tract obstruction; MLLT10, histone lysine
methyltransferase DOT1L cofactor gene; NDD, neurodevelopmental delay;
pLI, probability of loss-of-function intolerance; PTEN, phosphatase and tensin
homolog gene; TCF12, transcription factor 12 gene; TFRC, transferrin receptor
gene; ToF, tetralogy of Fallot; VATER, vertebral, anal, tracheal, esophageal, and
renal abnormalities; VSD, ventricular septal defect.
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tients with CHD and help determine causal associations, as well
as whether associations are modified by nongenetic factors.
Control participants were considerably older, potentially
introducing survivor bias that would enhance the burden of CR
variants in patients with CHD. Depth of sequencing precluded
differentiation of variants as germline or high-level mosaic. We
analyzed only LoF variants since defining missense variants as
damaging requires detailed functional assessments, and thus
our data provide only a conservative estimate of CR variants in
patients with CHD. This also precluded assessment of burden
for CR genes that operate by gain-of-function mechanisms in
cancer, such as protein tyrosine phosphatase non-receptor type
11 (PTPN11) and other RASopathy genes.14
Conclusions
Decades of therapeutic progress enable long-term survival for
newborns with CHD, and current estimates indicate 6 in 1000
adults are survivors of CHD.1 The recognition that CHD geno-
types influence CR can promote clinical surveillance and early
interventions and further promote lifelong health in adult pa-
tients with CHD. Additionally, we suggest that mechanistic
studies into the molecular and cellular processes that are dis-
rupted by damaging variants in CHD and cancer genes may
uncover insights that inform new treatment strategies for both
disorders.
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